We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Handle with Care: Ensuring LNP Quality for Better Genetic Medicines

Lipid nanoparticles (LNPs) are widely adopted vehicles for oligonucleotide-based therapeutics and vaccines. LNPs are composed of helper lipids, PEGylated lipids, and ionizable lipids. Their detailed characterization and related impurities are of major importance for developing a successful product. Specifically, N-oxide-based impurities, leading to the loss in function of mRNA, pose a major concern.

In this webinar, Adam Crowe from SCIEX will look at how an ionizable lipid, commonly known as DLin-MC3-DMA (MC3), was analyzed with liquid chromatography coupled to mass spectrometry (LC-MS) using electron-activated dissociation (EAD), a novel type of low-energy electron-impact fragmentation.